Carlsbad-based Tyra Biosciences , Inc. announced a change in its Board of Directors, according to a recent SEC filing. On ...

CARLSBAD, Calif. - Tyra Biosciences , Inc. (NASDAQ:TYRA), a biotech firm specializing in precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

Shares of TYRA opened at $15.10 on Monday. Tyra Biosciences has a 1 year low of $12.17 and a 1 year high of $29.60. The company has a market capitalization of $764.11 million, a price-to-earnings ...

Every investor in Tyra Biosciences, Inc. (NASDAQ:TYRA) should be aware of the most powerful shareholder groups. We can see that private equity firms own the lion's share in the company with 44% ...

CARLSBAD, Calif., Jan. 10, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target ...

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Tyra Bioscience (TYRA – Research Report) today and set a price ...

UBS analyst Eliana Merle initiated coverage of Tyra Biosciences (TYRA) with a Buy rating and $28 price target Tyra Biosciences is a clinical-stage biotech company with a drug, TYRA-300 ...

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology.

Key Insights Significant control over Tyra Biosciences by private equity firms implies that the general public has ...